|
Re: no interest
|
3
|
Resverlogix Corp.
|
Jul 22, 2019 11:18AM
|
|
Re: No mention of efficacy again...
|
6
|
Resverlogix Corp.
|
Mar 29, 2019 03:04PM
|
|
Re: No mention of efficacy again...
|
4
|
Resverlogix Corp.
|
Mar 29, 2019 06:38PM
|
|
Re: No news
|
6
|
Resverlogix Corp.
|
Sep 16, 2022 05:16PM
|
|
Re: No news
|
4
|
Resverlogix Corp.
|
Sep 17, 2022 11:08AM
|
|
Re: No news
|
3
|
Resverlogix Corp.
|
Sep 15, 2022 12:38PM
|
|
Re: Not a bad first PR for 2020....
|
7
|
Resverlogix Corp.
|
Jan 13, 2020 10:19AM
|
|
Re: Not a bad first PR for 2020....
|
5
|
Resverlogix Corp.
|
Jan 13, 2020 10:51AM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
3
|
Resverlogix Corp.
|
Dec 03, 2021 09:03AM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
3
|
Resverlogix Corp.
|
Nov 29, 2021 06:47PM
|
|
Re: Not much encouragement today
|
5
|
Resverlogix Corp.
|
Jan 21, 2022 07:18PM
|
|
Re: Not out of the woods yet with COVID-19
|
8
|
Resverlogix Corp.
|
Feb 19, 2022 08:51AM
|
|
Re: Not quite a breakout yet....
|
4
|
Resverlogix Corp.
|
Apr 20, 2019 05:22PM
|
|
Re: Number of outstanding warrants + impact
|
6
|
Resverlogix Corp.
|
Nov 26, 2019 08:53AM
|
|
Re: Of relevance to Resverlogix's planned Fabry Disease trial
|
7
|
Resverlogix Corp.
|
Aug 09, 2019 02:39PM
|
|
Re: Ok hepalink down 9.2%
|
2
|
Resverlogix Corp.
|
Sep 29, 2019 11:40PM
|
|
Re: On or about September 30, 2019
|
3
|
Resverlogix Corp.
|
Sep 25, 2019 10:48AM
|
|
Re: On or about September 30, 2019
|
4
|
Resverlogix Corp.
|
Sep 25, 2019 11:51AM
|
|
Re: On or about September 30, 2019
|
5
|
Resverlogix Corp.
|
Sep 25, 2019 11:53AM
|
|
Re: Option #2 and Option #3 questions
|
7
|
Resverlogix Corp.
|
Oct 27, 2020 02:16PM
|
